Need Help With This Product?
Our specialists are here to help you find the best product for your application.
Cardiac progenitor cells (CPCs) are able to proliferate and have the capacity to differentiate into cardiomyocytes. Thus, these cells are attractive targets in drug development applications for regenerative medicine programs focused on developing myocardial infarction and congestive heart failure treatments. They are also ideal for identifying and helping to avoid drug-mediated cardiac developmental toxicity problems across multiple programs, an application for which scientists require consistent and dependable access to human CPCs.
Derived from human iPS cells, FCDI's iCell® Cardiac Progenitor Cells provide a robust, reproducible, and relevant source of cells to advance drug development and cardiac regenerative medicine programs. Benefits include:
iCell Cardiac Progenitor Cells differentiated into cardiomyocytes as indicated by the increase in cTNT expression in the induced condition. Acquisition and analysis were performed using a BD Accuri C6 Flow Cytometer (BD Biosciences). iCell Cardiac Progenitor Cells were plated in the presence of XAV939/SB431542 for 2 days and assayed on day 8 post-plating
In this representative experiment, cell proliferation of iCell Cardiac Progenitor Cells was induced as indicated by the increase in the Hoechst 33342+ /NKX2.5+ /cTNT– cell population in the treatment condition. Acquisition and analysis were performed using the ImageXpress Micro System and MetaXpress Software. iCell Cardiac Progenitor Cells were plated in the presence of bFGF for 2 days and assayed on day 2 post plating.